Skip to main content
. 2001 Oct;45(10):2733–2739. doi: 10.1128/AAC.45.10.2733-2739.2001

TABLE 4.

Grade III or IV adverse events (severe or life threatening) possibly or probably related to the study drug

Group No. of subjects who received:
Total no. of subjects
Placebo Tenofovir DF dose (mg) of:
75 150 300 600
All subjects 11 12 8 8 10 49
Subjects with an event 1 1 0 4 0 6
Subjects with peripheral neuropathy 1 0 0 1 0 2
Subjects with CK elevation 1 1 0 4 0 6
Subjects with AST and/or ALT elevation 0 1 0 1 0 2